FIGURE 1.

SARS-CoV-2–specific cell-mediated immunity in SOT recipients and HCWs who received the mRNA-1273 and BNT162bs vaccines, respectively: (A) proportion with detectable S protein–specific IFN-γ–producing response at baseline, after the first vaccine dose vaccine (ie, 4 and 3 wk apart for mRNA-1273 and BNT162b2), and at 2 wk after the completion of the vaccine series; (B) kinetics of the number of S protein–specific IFN-γ–producing SFUs at the same time points. Red bars and whiskers represent median values and interquartile ranges, respectively. The cutoff value for positivity in the IFN-γ FluoroSpot assay (>25 SFUs/10⁶ PBMCs) is denoted by the blue dotted line. Comparisons between repeated measures were performed with the McNemar test or the Wilcoxon signed-rank test, as appropriate. HCW, healthcare worker; IFN-γ, interferon-γ; PBMC, peripheral blood mononuclear cell; S, SARS-CoV-2 spike glycoprotein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SFU, spot-forming unit; SOT, solid organ transplantation.